Re: Bayer en 2014
Ya he dicho que la veo en 120 en pocos meses.
Bayer Receives Approval for Riociguat in Japan for the Treatment
of Chronic-Thromboembolic Pulmonary Hypertension
Leverkusen, Germany, January 17, 2014 – Bayer HealthCare has received approval for
riociguat under the name Adempas® for the treatment of adults with inoperable chronicthromboembolic
pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after
surgical treatment by the Ministry of Health, Labour and Welfare (MHLW) in Japan. The
MHLW granted an orphan drug designation for riociguat in the CTEPH indication in
September 2011.
“The approval of riociguat as the first approved drug treatment for this severe, lifethreatening
disease is great news for patients in Japan,” said Kemal Malik (MB, BS),
Member of the Bayer HealthCare Executive Committee and Head of Global
Development. “Riociguat achieves meaningful clinical improvements, which is a much
needed step forward for patients whose CTEPH is inoperable or whose disease is
persistent or recurrent